Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates

Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough